HABA Laboratories,Inc.
Fiscal Year Ending March 2027 — Second Quarter (Interim) Financial Summary [Japanese GAAP] (Consolidated)
For the interim period of the fiscal year ending March 2027, consolidated net sales were 5,210,721 thousand yen, down 6.1% year-over-year. Operating income was 28,514 thousand yen, ordinary income was 26,771 thousand yen, and interim net income attributable to owners of parent was 5,221 thousand yen, representing a steep decline. Net assets at the interim period-end were 9,390,178 thousand yen and the equity ratio was 79.9%. Full-year forecasts for 2027 remain unchanged. Management continues initiatives to strengthen the operating base, including logistics integration and introduction of approx. new brands.
Key Figures
- Net Sales: 5,210,721 thousand yen (YoY -6.1%)
- Operating Income: 28,514 thousand yen (YoY -88.9%)
- Interim Net Income Attributable to Owners of Parent: 5,221 thousand yen (YoY -97.2%)
AI要約
Overview of Results
This report discloses consolidated results for the interim period of the fiscal year ending March 2027. Net sales amounted to 5,210,721 thousand yen, a 6.1% decrease from the same period last year. The core mail-order business faced challenges acquiring new customers, and store sales declined due to natural disasters and reduced tourism. Both the cosmetics and health food categories fell short of the prior year, resulting in substantial decreases in operating income, ordinary income and interim net income. The company will continue cost reduction and profit-structure reforms, reorganization of skin-concern-specific product lines, and strengthening of digital initiatives.
Outlook and Financial Position
The company will promote personnel capital strengthening, logistics integration, review of unprofitable stores, and SKU optimization under the Phase II medium-term plan. The full-year forecast for fiscal 2027 remains unchanged from the time of publication. Cash and cash equivalents stood at 4,770,477 thousand yen, net assets were 9,390,178 thousand yen, and the equity ratio improved from 76.2% to 79.9%. Dividend forecasts remain unchanged.
HABA Laboratories,Inc.
Company overview · Stock price · Financial data · All IR
